Gene-Disorder Association · Article
Gene
GABRG2 Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2
×
First reported
2003
Supporting publications
6
Manually curated Approved treatment annotated
Association Review
In brief The association between GABRG2 (Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2) and Dravet Syndrome is a manually-curated gene–disease association, with its 2 contributing sources — 1 of them expert-curated — recording a causative germline mutation.
Sources
2
Clinical variants
2
Symptoms
80
Compounds
1
Trials
5 of 12 via GABRG2 compounds
Publications
6
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Dravet Syndrome
The disorder 12 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features 63 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
ClinVar and variant evidence
Genetic basis 2 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access
07
Mechanism overlap
Shared mechanisms Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access
08
Interventions
Therapeutics 1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
09
Human studies
Clinical trials 12 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
6 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
11
Provenance
References & sources 16 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access